Stoke Therapeutics (STOK) Cash from Investing Activities (2018 - 2026)

Stoke Therapeutics has reported Cash from Investing Activities for 9 years, with the latest figure at $50.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 271.88% year-over-year to $50.7 million; the trailing twelve-month figure through Mar 2026 stood at -$149.8 million (down 44.22% YoY), and the FY2025 full-year result was -$186.8 million, down 73.82% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $50.7 million, up from -$61.1 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $67.3 million in Q3 2022, with the low at -$148.5 million in Q2 2025.
• Average Cash from Investing Activities over 5 years is -$10.8 million, with a median of $10.0 million recorded in 2024.
• Year-over-year, Cash from Investing Activities slumped 66459.8% in 2022 and jumped 15977.4% in 2023.
• Tracing STOK's Cash from Investing Activities over 5 years: stood at $22.5 million in 2022, then tumbled by 34.32% to $14.8 million in 2023, then plunged by 94.46% to $819000.0 in 2024, then plunged by 7555.56% to -$61.1 million in 2025, then soared by 183.02% to $50.7 million in 2026.
• The last three Cash from Investing Activities figures came in at $50.7 million (Q1 2026), -$61.1 million (Q4 2025), and $9.1 million (Q3 2025), per Business Quant data.

Peer Comparison